Company intelligence / Profile preview

BCTG Acquisition

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

BCTG Acquisition was a special purpose acquisition company (SPAC) formed to acquire and take public a biotechnology business; it completed a reverse merger with Tango Therapeutics in 2021, and ceased to exist as an independent entity after the merger.[1][3][11]

Industry: Investors

Partnerships

Boxer Capital (sponsor)Tango Therapeutics (acquisition target)PIPE investors including Avoro, Bain Capital Life Sciences, Blackrock, EcoR1, Farallon, Fidelity, Foresite, Janus Henderson, Logos, RA Capital, Samsara BioCapital, Southpoint, Surveyor Capital, Woodline, Casdin Capital, Cormorant Asset Management, Gilead Sciences

Beyond the preview

Go deeper on BCTG Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCTG Acquisition.

Explore the full profile